4D Molecular Therapeutics, Inc.

FDMT · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders2.9%

Institutions105.9%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$85.21M	$37000	$18.04M	$13.36M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$159.55M	-$187.84M	-$71.33M	-$56.66M
Operating income as a percentage of revenue.	-187.2%	-507678.4%	-395.5%	-424.0%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$140.11M	-$160.87M	-$71.32M	-$56.69M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.42	$-2.98	$-2.57	$-8.82
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.42	$-2.98	–	–

Balance Sheet

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$60.24M	$149.34M	$153.00M	$276.73M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$566.71M	$560.38M	$353.49M	$288.33M
Everything the company owes — debt, unpaid bills, and other obligations.	$61.05M	$49.78M	$34.38M	$31.94M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$505.66M	$510.61M	$319.11M	$256.39M

Cash Flow Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$109.08M	-$134.59M	-$69.13M	-$50.91M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$536000	$3.79M	$9.11M	$1.00M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$109.62M	-$138.37M	-$78.24M	-$51.91M

	You	Peer avg
P/E	–	2.9
Revenue Growth	+25106.7%	-22.6%
ROE	-43.3%	-4.8%

4D Molecular Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison